IDEAYA Biosciences, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
IDEAYA Biosciences, Inc. (IDYA) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $10.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-04
- IDEAYA Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $7.79M, a 60.91% increase year-over-year.
- IDEAYA Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $2.73M, a 5.15% decline year-over-year.
- IDEAYA Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$4.80M, a 311.04% decline year-over-year.
- IDEAYA Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $7.51M, a 159.34% increase year-over-year.
- IDEAYA Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $10.43M, a 3.40% decline from fiscal 2024.
- IDEAYA Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $10.79M, a 560.18% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $1.64M, a 64.24% decline from fiscal 2022.
- IDEAYA Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $4.57M, a 8.55% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $10.52M 10-Q · filed 2026-08-04 | $5.72M derived: sum of 3 quarters · filed 2026-08-04 | $13.23M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $2.73M 10-Q · filed 2026-05-05 | -$2.07M derived: sum of 2 quarters · filed 2026-05-05 | $5.44M derived: sum of 3 quarters · filed 2026-05-05 | $10.28M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $2.71M derived: sum of 2 quarters · filed 2026-02-17 | $7.55M derived: sum of 3 quarters · filed 2026-08-04 | $10.43M 10-K · filed 2026-02-17 |
| 2025-09-30 | $7.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $12.35M derived: sum of 2 quarters · filed 2026-08-04 | $15.23M 10-Q · filed 2025-11-04 | $17.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $4.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $7.72M 10-Q · filed 2026-08-04 | $9.99M derived: sum of 3 quarters · filed 2026-08-04 | $12.89M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $2.88M 10-Q · filed 2026-05-05 | $5.15M derived: sum of 2 quarters · filed 2026-05-05 | $8.04M derived: sum of 3 quarters · filed 2026-05-05 | $14.94M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $5.17M derived: sum of 2 quarters · filed 2026-02-17 | $12.07M derived: sum of 3 quarters · filed 2026-02-17 | $10.79M 10-K · filed 2026-02-17 |
| 2024-09-30 | $2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $9.79M derived: sum of 2 quarters · filed 2025-11-04 | $8.52M 10-Q · filed 2025-11-04 | $11.00M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $6.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $5.63M 10-Q · filed 2025-08-05 | $8.11M derived: sum of 3 quarters · filed 2026-02-17 | $10.52M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | -$1.27M 10-Q · filed 2025-05-06 | $1.21M derived: sum of 2 quarters · filed 2026-02-17 | $3.62M derived: sum of 3 quarters · filed 2026-02-17 | $781.00K derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $4.89M derived: sum of 2 quarters · filed 2026-02-17 | $2.05M derived: sum of 3 quarters · filed 2026-02-17 | $1.64M 10-K · filed 2026-02-17 |
| 2023-09-30 | $2.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$427.00K derived: sum of 2 quarters · filed 2024-11-04 | -$846.00K 10-Q · filed 2024-11-04 | -$523.00K derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | -$2.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$3.26M 10-Q · filed 2024-08-06 | -$2.94M derived: sum of 3 quarters · filed 2025-02-18 | -$1.79M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | -$419.00K 10-Q · filed 2024-05-07 | -$96.00K derived: sum of 2 quarters · filed 2025-02-18 | $1.05M derived: sum of 3 quarters · filed 2025-02-18 | $4.01M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $1.47M derived: sum of 2 quarters · filed 2025-02-18 | $4.43M derived: sum of 3 quarters · filed 2025-02-18 | $4.57M 10-K · filed 2025-02-18 |
| 2022-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $4.11M derived: sum of 2 quarters · filed 2023-11-07 | $4.25M 10-Q · filed 2023-11-07 | $4.72M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $2.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.10M 10-Q · filed 2023-08-10 | $3.58M derived: sum of 3 quarters · filed 2024-02-20 | $5.59M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $140.00K 10-Q · filed 2023-05-09 | $616.00K derived: sum of 2 quarters · filed 2024-02-20 | $2.63M derived: sum of 3 quarters · filed 2024-02-20 | $4.97M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $476.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $2.49M derived: sum of 2 quarters · filed 2024-02-20 | $4.83M derived: sum of 3 quarters · filed 2024-02-20 | $4.21M 10-K · filed 2024-02-20 |
| 2021-09-30 | $2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $4.35M derived: sum of 2 quarters · filed 2022-11-08 | $3.74M 10-Q · filed 2022-11-08 | $5.54M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.72M 10-Q · filed 2022-08-15 | $3.53M derived: sum of 3 quarters · filed 2023-03-07 | $4.97M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | -$615.00K 10-Q · filed 2022-05-10 | $1.19M derived: sum of 2 quarters · filed 2023-03-07 | $2.63M derived: sum of 3 quarters · filed 2023-03-07 | $1.99M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $3.24M derived: sum of 2 quarters · filed 2023-03-07 | $2.61M derived: sum of 3 quarters · filed 2023-03-07 | $2.99M 10-K · filed 2023-03-07 |
| 2020-09-30 | $1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $802.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.19M 10-Q · filed 2021-11-15 | $2.22M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-06-30 | -$635.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$251.00K 10-Q · filed 2021-08-10 | $779.00K derived: sum of 3 quarters · filed 2022-03-18 | $834.00K derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-03-31 | $384.00K 10-Q · filed 2021-05-10 | $1.41M derived: sum of 2 quarters · filed 2022-03-18 | $1.47M derived: sum of 3 quarters · filed 2022-03-18 | $3.14M derived: sum of 4 quarters · filed 2022-03-18 |
| 2019-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $1.08M derived: sum of 2 quarters · filed 2022-03-18 | $2.76M derived: sum of 3 quarters · filed 2022-03-18 | $2.03M 10-K · filed 2022-03-18 |
| 2019-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.73M derived: sum of 2 quarters · filed 2020-11-12 | $1.00M 10-Q · filed 2020-11-12 | $1.75M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $945.00K 10-Q · filed 2020-08-12 | $1.70M derived: sum of 3 quarters · filed 2021-03-23 | $1.77M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-03-31 | -$727.00K 10-Q · filed 2020-05-12 | $28.00K derived: sum of 2 quarters · filed 2021-03-23 | $103.00K derived: sum of 3 quarters · filed 2021-03-23 | |
| 2018-12-31 | $755.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $830.00K derived: sum of 2 quarters · filed 2021-03-23 | $1.67M 10-K · filed 2021-03-23 | |
| 2018-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $917.00K 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $842.00K 10-Q · filed 2019-08-12 | |||
| 2017-12-31 | $1.01M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |